potassium voltage-gated channel modifier subfamily V member 2Genealiases: CDSRR · KV11.1 · Kv8.2 · RCD3B
Q-omics provides the consensus-scored KCNV2 profile across patient tissues and cancer cell-line models. KCNV2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, KCNV2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, KCNV2 RNA expression shows 18,579 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KIRC, and THYM as cancer lineages where KCNV2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNV2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNV2 survival associations across molecular data types. KCNV2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNV2 RNA expression–survival associations across cancer types. High KCNV2 expression shows unfavorable associations in LIHC, ACC and UVM, but favorable associations in READ, UCS and SCLC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for KCNV2 RNA expression.
This table summarizes KCNV2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNV2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNV2 shows lower tumor expression in THCA and higher tumor expression in KIRC, KIRP, HNSC, STAD and COAD. The KIRC box plot shows higher KCNV2 RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p < 0.001).
This table shows molecular features associated with KCNV2 in patient tissues and cancer cell lines. In patient samples, KCNV2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNV2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
